55
Participants
Start Date
February 25, 2019
Primary Completion Date
February 15, 2022
Study Completion Date
February 15, 2024
Pembrolizumab (MK-3475)
200 mg (adult participants) or 2 mg/kg (up to 200 mg; pediatric participants) on Day 1 of each 3-week cycle (Q3W) IV up to 35 administrations (approximately 2 years).
Auckland City Hospital ( Site 0427), Auckland
Melanoma Institute Australia ( Site 0400), North Sydney
Calvary Mater Newcastle ( Site 0402), Waratah
Laura and Isaac Perlmutter Cancer Center at NYU Langone Health ( Site 0006), New York
Icahn School of Medicine at Mount Sinai ( Site 0004), New York
Hopital de la Cote de Nacre - Caen ( Site 0204), Caen
IEO Istituto Europeo di Oncologia ( Site 0223), Milan
Hospital Universitario La Paz ( Site 0263), Madrid
CHU de Bordeaux- Hopital Saint Andre ( Site 0203), Bordeaux
Istituto Oncologico Veneto ( Site 0221), Padua
C.H.R.U. de Tours. Hopital Trousseau ( Site 0202), Chambray-lès-Tours
Hospital General Universitario de Valencia ( Site 0262), Valencia
Azienda Ospedaliera Universitaria Senese ( Site 0224), Siena
CHRU Lille - Hopital Claude Huriez ( Site 0200), Lille
Istituto Nazionale Tumori Fondazione Pascale ( Site 0222), Napoli
Hopital Ambroise Pare Boulogne ( Site 0201), Boulogne-Billancourt
Moncton Hospital - Horizon Health Network ( Site 0055), Moncton
Princess Margaret Cancer Centre ( Site 0051), Toronto
Hospital Universitari Vall d Hebron ( Site 0264), Barcelona
Hospital Clinic de Barcelona ( Site 0261), Barcelona
Karolinska Universitetssjukhuset Solna ( Site 0281), Solna
Sahlgrenska Universitetssjukhuset ( Site 0282), Gothenburg
Merck Sharp & Dohme LLC
INDUSTRY